NSEI:ABBOTINDIA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Abbott India Limited operates as a pharmaceutical company in India.

Rewards

Earnings grew by 31.6% over the past year

Pays a reliable dividend of 1.56%

Risk Analysis

No risks detected for ABBOTINDIA from our risk checks.


Snowflake Analysis

Outstanding track record with flawless balance sheet and pays a dividend.


Similar Companies

Share Price & News

How has Abbott India's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ABBOTINDIA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

7.1%

ABBOTINDIA

6.9%

IN Pharmaceuticals

-0.07%

IN Market


1 Year Return

91.1%

ABBOTINDIA

43.7%

IN Pharmaceuticals

1.4%

IN Market

Return vs Industry: ABBOTINDIA exceeded the Indian Pharmaceuticals industry which returned 43.7% over the past year.

Return vs Market: ABBOTINDIA exceeded the Indian Market which returned 1.4% over the past year.


Shareholder returns

ABBOTINDIAIndustryMarket
7 Day7.1%6.9%-0.07%
30 Day2.2%10.4%3.3%
90 Day-12.5%16.9%18.2%
1 Year92.5%91.1%45.8%43.7%3.3%1.4%
3 Year264.9%259.5%23.2%19.6%-1.6%-6.2%
5 Year263.8%252.5%1.1%-2.5%25.0%15.6%

Price Volatility Vs. Market

How volatile is Abbott India's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Abbott India undervalued compared to its fair value and its price relative to the market?

57.33x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ABBOTINDIA (₹16009.1) is trading above our estimate of fair value (₹5339.25)

Significantly Below Fair Value: ABBOTINDIA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ABBOTINDIA is poor value based on its PE Ratio (57.3x) compared to the IN Pharmaceuticals industry average (21.5x).

PE vs Market: ABBOTINDIA is poor value based on its PE Ratio (57.3x) compared to the Indian market (13x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABBOTINDIA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABBOTINDIA is overvalued based on its PB Ratio (14x) compared to the IN Pharmaceuticals industry average (1.9x).


Next Steps

Future Growth

How is Abbott India forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Abbott India has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Abbott India performed over the past 5 years?

20.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABBOTINDIA has high quality earnings.

Growing Profit Margin: ABBOTINDIA's current net profit margins (14.5%) are higher than last year (12.2%).


Past Earnings Growth Analysis

Earnings Trend: ABBOTINDIA's earnings have grown significantly by 20.2% per year over the past 5 years.

Accelerating Growth: ABBOTINDIA's earnings growth over the past year (31.6%) exceeds its 5-year average (20.2% per year).

Earnings vs Industry: ABBOTINDIA earnings growth over the past year (31.6%) exceeded the Pharmaceuticals industry 15.9%.


Return on Equity

High ROE: ABBOTINDIA's Return on Equity (24.4%) is considered high.


Next Steps

Financial Health

How is Abbott India's financial position?


Financial Position Analysis

Short Term Liabilities: ABBOTINDIA's short term assets (₹32.0B) exceed its short term liabilities (₹8.9B).

Long Term Liabilities: ABBOTINDIA's short term assets (₹32.0B) exceed its long term liabilities (₹2.2B).


Debt to Equity History and Analysis

Debt Level: ABBOTINDIA is debt free.

Reducing Debt: ABBOTINDIA had no debt 5 years ago.

Debt Coverage: ABBOTINDIA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ABBOTINDIA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Abbott India current dividend yield, its reliability and sustainability?

1.56%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: ABBOTINDIA's dividend (1.56%) is higher than the bottom 25% of dividend payers in the Indian market (0.67%).

High Dividend: ABBOTINDIA's dividend (1.56%) is low compared to the top 25% of dividend payers in the Indian market (2.78%).


Stability and Growth of Payments

Stable Dividend: ABBOTINDIA's dividends per share have been stable in the past 10 years.

Growing Dividend: ABBOTINDIA's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (38.3%), ABBOTINDIA's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average board tenure


CEO

Anil Joseph (45 yo)

0.17

Tenure

Mr. Anil Joseph serves as Managing Director and Director at Abbott India Limited since June 2020. He comes with an excellent track record of over 25 years working with reputable companies across different ...


Board Members

NamePositionTenureCompensationOwnership
Rajiv Sonalker
CFO, Group Finance Director & Whole-time Director3yrs₹30.48mno data
Anil Joseph
MD & Director0.17yrno datano data
Ambati Venu
Additional Non Executive Non Independent Director3.92yrs₹65.08mno data
Munir Shaikh
Chairman of the Boardno data₹1.50mno data
Kaiyomarz Marfatia
Non-Executive Director9.42yrs₹15.90mno data
Sudarshan Jain
Independent Director1.33yrs₹5.94m0.0012%
₹ 3.9m
Anisha Motwani
Independent Director2.33yrs₹1.30mno data
Shalini Kamath
Independent Director0.83yrno datano data

2.3yrs

Average Tenure

59yo

Average Age

Experienced Board: ABBOTINDIA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Abbott India Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Abbott India Limited
  • Ticker: ABBOTINDIA
  • Exchange: NSEI
  • Founded: 1944
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹330.171b
  • Shares outstanding: 21.25m
  • Website: https://www.abbott.co.in

Number of Employees


Location

  • Abbott India Limited
  • Godrej BKC
  • 16th Floor, Plot C, “G” Block
  • Mumbai
  • Maharashtra
  • 400051
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
500488BSE (Mumbai Stock Exchange)YesEquity SharesININRSep 1999
ABBOTINDIANSEI (National Stock Exchange of India)YesEquity SharesININRSep 1999

Biography

Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women’s health, gastroenterology, metabolics, central nervous sy ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/03 12:47
End of Day Share Price2020/08/03 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.